Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy

American Journal of Transplantation

Volumn 11, Issue 3, 2011, Pages 470-477

  Willicombe, Michelle ^a   Brookes, P ^b   Santos Nunez, E ^b   Galliford, J ^a   Ballow, A ^b   Mclean, A ^a   Roufosse, C ^b   Cook, H T ^b   Dorling, A ^a   Warrens, A N ^b   Cairns, T ^a   Taube, D ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Alemtuzumab; Antibody mediated rejection; Donor specific antibodies; Highly sensitized; Steroid sparing regime

Indexed keywords

ALEMTUZUMAB; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; VIGAM;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY DONOR; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS; TACROLIMUS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79951972563     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03421.x     Document Type: Article

References (43)

1. El-Awar N, Lee J, Terasaki PI. HLA antibody identification with single antigen beads compared to conventional methods. Hum Immunol 2005; 66: 989-997. (Pubitemid 41790535)
2. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75: 43-49. (Pubitemid 36139693)
3. Zachary AA, Leffell MS. Detecting and monitoring human leukocyte antigen-specific antibodies. Hum Immunol 2008; 69: 591-604.
4. Gupta A, Iveson V, Varagunam M, Bodger S, Sinnott P, Thuraisingham RC. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: Are they relevant? Transplantation 2008; 85: 1200-1204.
5. Vaughan R, Shaw O. How much donor human leukocyte antigen-specific antibody is toomuch for a renal transplant? Transplantation 2008; 85: 1081-1082.
6. Patel AM, Pancoska C, Mulgaonkar S, Weng FL. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007; 7: 2371-2377. (Pubitemid 47347867)
7. Amico P, Honger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009; 87: 1681-1688.
8. Gibney EM, Cagle LR, Freed B, Warnell SE, Chan L, Wiseman AC. Detection of donor-specific antibodies using HLA-coated microspheres: Another tool for kidney transplant risk stratification. Nephrol Dial Transplant 2006; 21: 2625-2629. (Pubitemid 44644542)
9. Guidelines for the detection and characterisation of clinically relevant antibodies in transplantation. Available at:www.bshi.org.uk/BTS/BSHI. Accessed October 12, 2010.
10. Opelz G, Claas FH. Which human leukocyte antigen antibodies are really clinically relevant? Hum Immunol 2009; 70: 561-562.
11. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997; 350: 1193-1198. (Pubitemid 127445091)
12. Charpentier B, Rostaing L, Berthoux F et al. A three-arm study comparing immediate tacrolimus therapywith antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation 2003; 75: 844-851. (Pubitemid 36373458)
13. Mourad G, Garrigue V, Squifflet JP et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 2001; 72: 1050-1055. (Pubitemid 32924076)
14. Zarkhin V, Li L, Sarwal M. "To B or not to B?" B-cells and graft rejection. Transplantation 2008; 85: 1705-1714.
15. Tarlinton DM, Batista F, Smith KGC. The B-cell response to protein antigens in immunity and transplantation. Transplantation 2008; 85: 1698-1704.
16. Clatworthy MR, Watson CJ, Plotnek G et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009; 360: 2683-2685.
17. Parsons RF, Vivek K, Redfield RR et al. B-cell tolerance in transplantation: Is repertoire remodeling the answer? Expert Rev Clin Immunol 2009; 5: 703-723.
18. Bloom DD, Hu H, Fechner J, Knetchle SJ. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 2006; 81: 81-87. (Pubitemid 43122153)
19. Calne R, Friend P, Moffatt S et al. Prope tolerance, perioperative Campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701-1702. (Pubitemid 28254534)
20. Thomas PG, Woodside KJ, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 2007; 83: 1509-1512. (Pubitemid 46934076)
21. Vo AA, Wechsler EA, Wang J et al. Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am J Transplant 2008; 8: 144-149.
22. Kirk AD, Hale AD, Mannon RB et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003. 76: 120-129. (Pubitemid 36877125)
23. Knechtle SJ, Pirsch JD, Fechner JH et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003; 3: 722-730. (Pubitemid 36745245)
24. Flechner SM, Friend PJ, Brockmann J et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005; 5: 3009-3014. (Pubitemid 43923964)
25. Delgado JC, Eckels DD. Positive B-cell only flow cytometric crossmatch: Implications for renal transplantation. Exp Mol Pathol 2008; 85: 59-63.
26. Riethmüller S, Ferrari-Lacraz S, Müller MK et al. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation 2010; 90: 160-167.
27. Taylor CJ, Kosmoliaptsis V, Summers DM, Bradley JA. Back to the future: Application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. Hum Immunol 2009; 70: 563-568.
28. Borrows R, Chan K, Loucaidou M et al. Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. Transplantation 2006; 81: 125-128. (Pubitemid 43122160)
29. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753-760. (Pubitemid 351347767)
30. www.organdonation.nhs.uk/ukt/about-transplants/organ-allocation. Accessed June 4, 2010.
31. Lefaucheur C, Suberbielle-Boissel C, Hill GS et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Contrib Nephrol 2009; 162: 1-12.
32. Amico P, Hanger G, Steiger J, Schaub S. Utility of the virtual cross-match in solid organ transplantation. Curr Opin Organ Transplant 2009; 14: 656-661.
33. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk. Am J Transplant 2003; 3: 1488-1500. (Pubitemid 37541506)
34. Burns JM, Cornell LD, Perry DK, Pollinger HS, Gloor JM, Kremers WK. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684-2694.
35. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3: 665-673. (Pubitemid 36745238)
36. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735-739.
37. Garovoy MR, Rheinschmilt MA, Bigos M et al. Flow cytometry analysis: A high technology crossmatch technique facilitating transplantation. Transplant Proc 1983; 15: 1939-1944. (Pubitemid 14233896)
38. Wahrmann M, Bartel G, Exner M et al. Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Transpl Int 2009; 22: 982-989.
39. Böhmig GA, Bartel G, Wahrmann M. Antibodies, isotypes and complement in allograft rejection. Curr Opin Organ Transplant 2008; 13: 411-418.
40. Bindon CI, Hale G, Bruggemann M, Waldemann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med 1988; 168: 127-142.
41. Bartel G, Wahrmann M, Exner M et al. Determinants of the complement-fixing ability of recipient presensitization against HLA antigens. Transplantation 2007; 83: 727-733. (Pubitemid 46569190)
42. Griffiths EJ, Nelson RE, Dupont PJ, Warrens AN. Skewing of pretransplant anti-HLA class I antibodies of immunoglobulin G isotype solely toward immunoglobulin G1 subclass is associated with poorer renal allograft survival. Transplantation 2004; 77: 1771-1773. (Pubitemid 38780549)
43. Arnold ML, Zacher T, Dechant M et al. Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates. Tissue Antigens 2008; 72: 60-66. (Pubitemid 351841652)